Edition:
United Kingdom

Vascular Biogenics Ltd (VBLT.OQ)

VBLT.OQ on NASDAQ Stock Exchange Global Market

7.55USD
22 Jan 2018
Change (% chg)

$-0.20 (-2.58%)
Prev Close
$7.75
Open
$7.60
Day's High
$7.80
Day's Low
$7.45
Volume
43,227
Avg. Vol
61,462
52-wk High
$9.05
52-wk Low
$3.95

Select another date:

Wed, Dec 27 2017

BRIEF-Vascular Biogenics Says Top-Line Data From Globe Phase 3 Pivotal Trial Of VB-111 Expected In Q1 Of 2018

* VASCULAR BIOGENICS - TOP-LINE DATA FROM GLOBE PHASE 3 PIVOTAL TRIAL OF VB-111 EXPECTED IN Q1 OF 2018 Source text for Eikon: Further company coverage:

BRIEF-Vascular Biogenics Files For Mixed Shelf Of Up To $150 Mln - SEC Filing

* VASCULAR BIOGENICS LTD FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text: (http://bit.ly/2CY4IXN) Further company coverage:

BRIEF-VBL therapeutics prices 2.5 mln ordinary share offering

* VBL Therapeutics prices 2.5 million ordinary share offering

BRIEF-VBL Therapeutics announces proposed public offering of 2.5 mln shares of ordinary shares

* VBL Therapeutics announces proposed public offering of 2.5 million shares of ordinary shares Source text for Eikon: Further company coverage:

BRIEF-VBL therapeutics Q3 loss per share $0.24

* VBL Therapeutics announces third quarter 2017 financial results

BRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan

* VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan

BRIEF-VBL THERAPEUTICS OPENS NEW GENE THERAPY MANUFACTURING PLANT, HEADQUARTERS

* VBL THERAPEUTICS CELEBRATES OPENING OF ITS NEW GENE THERAPY MANUFACTURING PLANT AND COMPANY HEADQUARTERS

BRIEF-VBL Therapeutics says VB-111 given orphan drug designation in Europe

* VBL Therapeutics announces orphan drug designation for VB-111 in Europe

BRIEF-Vascular Biogenics reports Q2 loss per share $0.18

* Vbl therapeutics announces second quarter 2017 financial results

Select another date: